Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History SWTX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics SWTX

Max Ratio

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Forward Annual Dividend Yield
Consecutive Years
Forward Annual Dividend – USD
Consistent Years
Dividend CAGR 3Y
Continuous Dividends
Dividend CAGR 5Y
Payout Ratio TTM
Dividend CAGR 10Y
Ex Dividend Date

SpringWorks Therapeutics Inc

SWTX
Current price
46.99 USD 0 USD (0.00%)
Last closed 46.99 USD
ISIN US85205L1070
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 3 540 649 728 USD
Yield for 12 month +27.59 %
1Y
3Y
5Y
10Y
15Y
SWTX
21.11.2021 - 28.11.2021

SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. It offers OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor for the treatment of desmoid tumors; and GOMEKLI (mirdametinib), an oral small molecule inhibitor of MEK1 and MEK2 for the treatment of adult and pediatric patients two years of age and older with neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN). The company also develops Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer; and mirdametinib for the treatment of solid tumors harboring other MAPK aberrations, including for the treatment of pediatric and young adult patients with low-grade gliomas that is in Phase 1/2 clinical trial. In addition, its products under development include Brimarafenib (BGB-3245), an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations. The company has license agreements with Pfizer Inc. for nirogacestat and mirdametinib; and Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain. SpringWorks Therapeutics, Inc. was founded in 2017 and is headquartered in Stamford, Connecticut. Address: 100 Washington Boulevard, Stamford, CT, United States, 06902

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

47.00 USD

P/E Ratio

Dividend Yield

Financials SWTX

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures SWTX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

+191 589 000 USD

Last Year

+5 447 000 USD

Current Quarter

+49 087 000 USD

Last Quarter

+61 549 000 USD

Current Year

+179 039 000 USD

Last Year

+5 025 000 USD

Current Quarter

+45 560 000 USD

Last Quarter

+55 995 000 USD
EBITDA -260 896 000 USD
Operating Margin TTM -164.07 %
Price to Earnings
Return On Assets TTM -28.47 %
PEG Ratio
Return On Equity TTM -51.57 %
Wall Street Target Price 47.00 USD
Revenue TTM 219 670 000 USD
Book Value 5.57 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 133.70 %
Dividend Yield
Gross Profit TTM 204 795 008 USD
Earnings per share -3.41 USD
Diluted Eps TTM -3.41 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY
Profit Margin -115.60 %

Stock Valuation SWTX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE 322.58
Enterprise Value Revenue 14.84
Price Sales TTM 16.12
Enterprise Value EBITDA -7.90
Price Book MRQ 8.48

Technical Indicators SWTX

For 52 Weeks

28.21 USD 62.00 USD
50 Day MA 46.50 USD
Shares Short Prior Month 6 243 194
200 Day MA 41.63 USD
Short Ratio 1.46
Shares Short 6 380 398
Short Percent 10.18 %